WestPark Capital initiated coverage of Enanta (ENTA) with a Buy rating and $24 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta Pharmaceuticals Appoints Interim Financial Officers
- Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement
- Enanta files EU patent infringement suit against Pfizer
- Enanta Pharmaceuticals: Hold Rating Amid Strategic Advances and Financial Constraints
- Enanta Pharmaceuticals: Promising Outlook with Key Data Readouts and Strong Virology Pipeline